Datapoint: Amylyx Pulls ALS Drug Off the Market

Amylyx Pharmaceuticals will pull its ALS drug Relyvrio from the market after it failed to outperform a placebo in a Phase 3 clinical trial, according to an April 4 report from the Associated Press. The drug’s 2022 FDA approval was based on a small clinical trial that showed it only moderately slowed the disease’s progression, a move that proved to be controversial. While Relyvrio is no longer available to new patients, Amylyx said current patients who want to continue taking the drug will be able to enroll in a program to obtain it at no cost. Prior to Amylyx’s announcement, Relyvrio held covered or better status for 57% of all insured lives under the pharmacy benefit, largely with utilization management restrictions applied.

SOURCE: MMIT Analytics, as of 4/10/24

0 Comments
© 2024 MMIT
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 16

Datapoint: Cigna, Oscar to End Small Group Partnership

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 15

Datapoint: FDA Approves Pfizer’s Hemophilia B Treatment

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 14

Datapoint: Sandoz Reaches Agreement With Amgen to Launch Prolia, Xgeva Biosimilars

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today